SavedAdd your journal

Journals / Respiratory Case Reports / 2019 / Cilt: 8 - Sayı: 1

Pulmonary Toxicity Secondary to Fluorouracil, Leucoverin and Oxaliplatin Treatment: A Case Report

Fluorourasil, Leucoverin ve Oxaliplatin Tedavisine Sekonder Akciğer Toksisitesi: Olgu Sunumu

Fatma TOKGÖZ AKYIL
Mustafa AKYIL
Erdem ŞEN
Meltem AĞCA
Tülin SEVİM
Pages
26–30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Presently described is the case of a female patient with interstitial lung disease secondary to undergoing a FOLFOX regimen for metastatic esophagus cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To date, 5-fluorourasil, leucovorin, and oxaliplatin (FOLFOX) continues to be used as a first-line treatment for advanced or metastatic gastrointestinal system tumors.
📊
Key Findings & Data:Though associated hematological, gastrointestinal, and neurosensory toxicities are widely known, pulmonary toxicity has solely been described in case reports.
💡
Conclusion & Impact:Presently described is the case of a female patient with interstitial lung disease secondary to undergoing a FOLFOX regimen for metastatic esophagus cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

To date, 5-fluorourasil, leucovorin, and oxaliplatin (FOLFOX) continues to be used as a first-line treatment for advanced or metastatic gastrointestinal system tumors. Though associated hematological, gastrointestinal, and neurosensory toxicities are widely known, pulmonary toxicity has solely been described in case reports. Early diagnosis and treatment is extremely important, since the toxicity may lead to rapid deterioration and mortality. Presently described is the case of a female patient with interstitial lung disease secondary to undergoing a FOLFOX regimen for metastatic esophagus cancer.

Özet

Günümüzde, FOLFOX (5-fluorourasil, leucoverin ve oxaliplatin) ileri evre veya metastatik gastrointestinal sistem tümörlerinde ilk sırada kullanılan kemoterapötik rejimdir. Bu rejimin hematolojik, gastrointestinal ve sensörinöral sistem ile ilgili yan etkileri bilinmesine karşın pulmoner toksisitesi sınırlı sayıda olgu bildirimleri düzeyindedir. Hızla ilerleyerek mortal seyredebileceğinden akciğer toksisitesinin erken farkındalığı ve tedavisi önemlidir. Bu yazıda, metastatik özofagus kanseri nedeniyle kullanılan FOLFOX tedavisine sekonder gelişen interstisyel akciğer hastalığı olgusu nadir olması nedeniyle sunulmuştur.

🔖

Cite This Article

AKYIL, F. T., AKYIL, M., ŞEN, E., AĞCA, M., SEVİM, T. (2019). Pulmonary Toxicity Secondary to Fluorouracil, Leucoverin and Oxaliplatin Treatment: A Case Report. Respiratory Case Reports, Cilt: 8 - Sayı: 1, 26–30. https://ajindex.com/articles/297646

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Schwaiblmair M, Behr W, Haeckel T, Märkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J 2012
  2. [CrossRef] 2. Niederhuber JE, Armitage JO, Doroshow JH, et al. Pulmonary toxicity of systemic anticancer therapies
  3. In Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia: Elsevier
  4. National Institute of Health and Clinical Excellence: The Diagnosis and Management of Colorectal Cancer. 2011. https://pathways.nice.org.uk/pathways/colorectal-cancer (accessed May 5, 2018). 4. Kim YS, Hong J, Sym SJ, Park SH, Park J, Cho EK, et al. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer. Cancer Res Treat 2010
  5. [CrossRef] 5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004
  6. 23– 30. [CrossRef] 6. Homma T, Kurokawa M, Yamamoto Y, Matsukura S, Ieki K, Suzuki S, et al. Oxaliplatin-induced lung injury with allergic reaction. Chin J Cancer Res 2011
  7. 232–5. [CrossRef] 7. Lee EJ, Lee SY, In KH, Kim CH, Park S. Organizing pneumonia associated with oxaliplatin-combined chemotherapy: a case report. Med Princ Pract 2012
  8. 89–92. [CrossRef] 8. 8. Trisolini R, Lazzari Agli L, Tassinari D, Rondelli D, Cancellieri A, Patelli M, et al. Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur Respir J 2001
  9. 243–5. 9. Gagnadoux F, Roiron C, Carrie E, Monnier-Cholley L, Lebeau B. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Am J Clin Oncol 2002
  10. 388–90. [CrossRef] 10. Wilcox BE, Ryu JH, Kalra S. Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases. Respir Med 2008
  11. 273–9. [CrossRef] 11. Moskovitz M, Wollner M, Haim N. Oxaliplatin-induced pulmonary toxicity in gastrointestinal malignancies: two case reports and review of the literature. Case Rep Oncol Med 2015
  12. 341064. [CrossRef] 12. Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, et al. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Ann Oncol 2010
  13. 2005–10. [CrossRef] 13. Rub